Where to fit in at AstraZeneca

AstraZeneca plc's decision to stop discovery efforts in previously key indications does not mean the company is no longer interested in developing drugs in those areas - it just intends to focus its internal R&D where it thinks it has a competitive edge. Consequently, biotechs with programs in the discontinued areas still have an opportunity to do deals with the company, particularly where the pharma thinks its clinical development engine can add value.

AstraZeneca will cease discovery efforts in thrombosis; acid reflux; ovarian and bladder cancers; systemic scleroderma; schizophrenia; bipolar disorder; depression and anxiety; HCV; and vaccines other than respiratory syncytial virus (RSV) and influenza...